Form 4: GeneDx Holdings CEO Sells Shares to Cover Tax Obligations After RSU Vesting
SEC Form 4 Filing
GeneDx Holdings CEO, Katherine Stueland, sold 3,661 shares of Class A Common Stock to cover tax obligations following the vesting of restricted stock units.
Summary
- Katherine Stueland, CEO of GeneDx Holdings Corp., engaged in transactions involving the company's Class A Common Stock on December 9, 2024.
- She acquired 6,547 shares through the vesting of restricted stock units (RSUs) at no cost.
- Following the vesting, she sold 3,661 shares at a weighted average price of $76.3719 per share to cover tax withholding obligations.
- The sales occurred in multiple transactions with prices ranging from $76.37 to $76.6892 per share.
- After these transactions, Stueland directly owns 62,897 shares of Class A Common Stock and 52,372 restricted stock units.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but rather a standard procedure. The sentiment is neutral to slightly positive as it indicates the executive is receiving compensation.
Industry Context
This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.
Comparison to Industry Standards
- The sale of shares to cover tax obligations is a standard practice among executives in publicly traded companies.
- Many companies use RSUs as part of their compensation packages, and the vesting schedules and tax implications are generally similar across the industry.
- Comparable companies in the biotech and healthcare sector also have executives who regularly file Form 4s for similar transactions.
Stakeholder Impact
- The sale of shares by the CEO has a minimal impact on shareholders as it is a routine transaction.
- The transaction does not affect the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| 2023-03-09 | Commencement date for the 4-year vesting period of the restricted stock units. |
| 2024-12-09 | Date of the RSU vesting and subsequent sale of shares. |
| 2024-12-11 | Date the SEC Form 4 was signed. |
Keywords
GeneDx Holdings, Katherine Stueland, Class A Common Stock, Restricted Stock Units, RSU, Tax Withholding, SEC Form 4, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.